Skip to main content

Table 6 Change in CV risk factors from baseline to last treatment (treated set)

From: Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

Mean (SEM) Linagliptin (n = 5758) Active comparators (n = 918) Placebo (n = 2618) Total comparators (n = 3536)
Total cholesterol, mg/dL     
Baseline 187 (0.6) 186 (1.3) 187 (0.9) 187 (0.8)
Change from baseline 1 (0.5) 2 (1.1) 2 (0.7) 2 (0.6)
LDL, mg/dL     
Baseline 107 (0.5) 104 (1.1) 107 (0.7) 106 (0.6)
Change from baseline 1 (0.4) 4 (0.9) 1 (0.6) 1 (0.5)
HDL, mg/dL     
Baseline 47 (0.2) 48 (0.4) 47 (0.3) 47 (0.2)
Change from baseline 1 (0.1) −1 (0.2) 1 (0.2) 1 (0.1)
Triglyceride, mg/dL     
Baseline 173 (1.8) 180 (4.1) 174 (2.9) 176 (2.4)
Change from baseline −7 (1.5) −8 (4.2) −3 (2.6) −5 (2.2)
HbA1c, %     
Baseline 8.1 (0.01) 7.8 (0.03) 8.3 (0.02) 8.1 (0.02)
Change from baseline −0.7 (0.01) −0.5 (0.03) −0.3 (0.02)* −0.3 (0.02)
Weight     
Baseline 79.5 (0.25) 83.8 (0.58) 81.1 (0.39) 81.9 (0.32)
Change from baseline −0.1 (0.05) 1.3 (0.15) 0.1 (0.07) 0.4 (0.06)
Systolic BP (mmHg)     
Baseline 131 (0.2) 134 (0.5) 132 (0.3) 132 (0.3)
Change from baseline −1 (0.2) −1 (0.5) −1 (0.3) −1 (0.3)
Diastolic BP (mmHg)     
Baseline 78 (0.1) 80 (0.3) 78 (0.2) 79 (0.2)
Change from baseline −1 (0.1) −1 (0.3) −1 (0.2) −1 (0.2)
Heart rate, bpm     
Baseline 74 (0.1) 73 (0.4) 74 (0.2) 74 (0.2)
Change from baseline 1 (0.1) −1 (0.3) 1 (0.3) 1 (0.2)
  1. BP, blood pressure; bpm, beats per minute; CV, cardiovascular; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
  2. *Analysis includes data obtained after initiation of glycemic rescue.